# US 2003/0229212 A1 · Non-affinity purification of proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229212 A1
- Document ID: US20030229212A1
- Status: Published application
- Kind: A1
- Application number: 10/423,299
- Filed: 2003-04-25
- Published: 2003-12-11
- Earliest claimed: 2002-04-26
- Assignees: Genentech, Inc.
- Inventors: Robert Fahrner; Deborah Follman; Benedicte Lebreton; Robert van Reis
- Web page: https://patentgrep.com/patent/US20030229212A1

## CPC

- C07K 16/065: {Purification, fragmentation}
- C07K 1/18: Ion-exchange chromatography
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C07K 1/36: by a combination of two or more processes of different types
- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a method for protein purification that involves the combination of non-affinity chromatography with HPTFF.

## Claims

### Claim 1

A method for purifying a target protein from a mixture containing a host cell protein, comprising subjecting said mixture to:
(a) a non-affinity purification step, followed by
(b) high-performance tangential-flow filtration (HPTFF), and
(c) isolating said protein in a purity containing less than 100 parts per million (ppm) of said host cell protein, wherein said method includes no affinity purification step.

### Claim 2

A method for purifying a target protein from a mixture containing a host cell protein, comprising subjecting said mixture to:
(a) a first non-affinity purification step, and
(b) a second non-affinity purification step, followed by
(c) high-performance tangential-flow filtration (HPTFF), and
(d) isolating said protein in a purity containing less than 100 parts per million (ppm) of said host cell protein, wherein said method includes no affinity purification step.

### Claim 3 (depends on 2)

The method of claim 2 wherein said first and second non-affinity purification steps are different and are selected from the group consisting of ion exchange chromatography and hydrophobic interaction chromatography.

### Claim 4 (depends on 3)

The method of claim 3 wherein said ion exchange chromatography is selected from the group consisting of cation exchange chromatography, anion exchange chromatography and mixed mode ion exchange chromatography.

### Claim 5 (depends on 4)

The method of claim 4 wherein said first and second affinity purification steps are cation exchange chromatography and anion exchange chromatography, in either order.

### Claim 6 (depends on 4)

The method of claim 4 wherein said first non-affinity purification step is cation exchange chromatography and said second non-affinity purification step is anion exchange chromatography.

### Claim 7 (depends on 6)

The method of claim 6 wherein said method consists of purification steps (a) - (c) followed by isolation step (d).

### Claim 8 (depends on 6)

The method of claim 6 wherein said cation exchange chromatography step is performed on a cation exchange ligand selected from the group consisting of carboxy-methyl, BAKERBOND ABX,™ sulphopropyl (SP), and sulphonyl.

### Claim 9 (depends on 6)

The method of claim 6 wherein said cation exchange chromatography step is performed on a cation exchange resin selected from the group consisting of carboxy-methyl-cellulose, BAKERBOND ABX,™ sulphopropyl immobilized on agarose, and sulphonyl immobilized on agarose.

### Claim 10 (depends on 6)

The method of claim 6 wherein said anion exchange ligand is selected from the group consisting of DEAE and quaternary ammonium ions.

### Claim 11 (depends on 6)

The method of claim 6 wherein said anion exchange resin is selected from the group consisting of DEAE cellulose, QAE SEPHADEX,™ and FAST SEPHAROSE.™

### Claim 12 (depends on 1, 2)

The method of claim 1 or 2 wherein the HPTFF is performed using a charged membrane.

### Claim 13 (depends on 1, 2)

The method of claim 1 or 2 wherein said host cell protein is Chinese Hamster Ovary Protein (CHOP).

### Claim 14 (depends on 1, 2)

The method of claim 1 or 2 wherein said target protein is an antibody.

### Claim 15 (depends on 14)

The method of claim 14 wherein said antibody is a monoclonal antibody.

### Claim 16 (depends on 14)

The method of claim 14 wherein said antibody is a polyclonal antibody.

### Claim 17 (depends on 14)

The method of claim 14 wherein said antibody is a humanized antibody.

### Claim 18 (depends on 14)

The method of claim 14 wherein said antibody is a human antibody.

### Claim 19 (depends on 14)

The method of claim 14 wherein said antibody is an antibody fragment.

### Claim 20 (depends on 14)

The method of claim 14 wherein said antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′)2 and Fv fragments, single-chain antibody molecules, diabodies, linear antibodies, bispecific antibodies and multispecific antibodies formed from antibody fragments.

### Claim 21 (depends on 14)

The method of claim 14 wherein said antibody specifically binds to an antigen selected from the group consisting of CD3, CD4, CD8, CD19, CD20, CD34, CD40, EGF receptor, HER2, HER3, HER4 receptor, LFA-1, Mac1, p150,95, VLA-4, ICAM-1, VCAM, av/b3 integrin, CD11a, CD18, CD11b, VEGF, IgE, flk2/flt3 receptor, obesity (OB) receptor, mpl receptor, CTLA-4, and polypeptide C.

### Claim 22 (depends on 14)

The method of claim 14 wherein said antibody is selected from the group consisting of anti-HER2; anti-CD20; anti-IL-8; anti-VEGF; anti-PSCA; anti-CD11a; anti-IgE; anti-Apo-2 receptor; anti-TNF-α, anti-Tissue Factor (TF); anti-CD3; anti-CD25; anti-CD34; anti-CD40; anti-tac; anti-CD4; anti-CD52; anti-Fc receptor; anti-carcinoembryonic antigen (CEA)antibodies; antibodies directed against breast epithelial cells; antibodies that bind to colon carcinoma cells; anti-CD33; anti-CD22; anti-EpCAM; anti-GpIIb/IIIa; anti-RSV; anti-CMV; anti-HIV; anti-hepatitis; anti-αvβ3; anti-human renal cell carcinoma; anti-human 17-1A; anti-human colorectal tumor; anti-human melanoma; anti-human squamous-cell carcinoma; and anti-human leukocyte antigen (HLA) antibodies.

### Claim 23 (depends on 14)

The method of claim 14 wherein said antibody is selected from the group consisting of anti-HER2 receptor, anti-VEGF, anti-IgE, anti-CD20, anti-CD11a, and anti-CD40 antibodies.

### Claim 24 (depends on 1, 2)

The method of claim 1 or 2 wherein the target protein is an immunoadhesin.

### Claim 25 (depends on 1, 2)

The method of claim 1 or 2 wherein the target protein is an antibody-like molecule.

### Claim 26 (depends on 25)

The method of claim 25 wherein said antibody-like molecule is a protein fused to, or conjugated with, a CH2/CH3 region.

### Claim 27 (depends on 26)

The method of claim 26 wherein said protein is selected from the group consisting of renin; growth hormones; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; factor VIIIC; factor IX; tissue factor; von Willebrands factor; Protein C; atrial natriuretic factor; lung surfactant; urokinase; human urine and tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES; human macrophage inflammatory protein (MIP-1-alpha); serum albumins; Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; beta-lactamase; DNase; IgE; cytotoxic T-lymphocyte associated antigens (CTLAs); inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; Protein A or D; rheumatoid factors; bone-derived neurotrophic factor (BDNF); neurotrophin-3, -4, -5, and -6 (NT-3, NT-4, NT-5, and NT-6), nerve growth factors; platelet-derived growth factor (PDGF); fibroblast growth factors; epidermal growth factor (EGF); transforming growth factors (TGF); insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins (IGFBPs); CD proteins; erythropoietin; osteoinductive factors; immunotoxins; bone morphogenetic proteins (BMPs); interferons-alpha, -beta, and -gamma; colony stimulating factors (CSFs); interleukins IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigens; transport proteins; homing receptors; addressing; regulatory proteins; integrins; tumor associated antigens; and fragments and thereof.

### Claim 28 (depends on 1, 2)

The method of claim 1 or 2, further comprising the step of incorporating the isolated protein into a pharmaceutical formulation.
